Inpatient Double-Blind Placebo-Controlled Withdrawal Study of 3,4-Diaminopyridine Base (3,4-DAP) in Subjects with Known Lambert-Eaton Myasthenic Syndrome (LEMS) [JPC 3,4-DAPPER]
Research Grant
Administered By
Duke Clinical Research Institute
Awarded By
Jacobus Pharmaceutical Company, Inc.
Start Date
November 16, 2018
End Date
April 30, 2020
Administered By
Duke Clinical Research Institute
Awarded By
Jacobus Pharmaceutical Company, Inc.
Start Date
November 16, 2018
End Date
April 30, 2020